Eli Lilly's Q3 2026 earnings release on October 29 will disclose Zepbound sales, with trader focus centered on whether tirzepatide revenue sustains its trajectory amid robust GLP-1 demand. Q2 2026 Zepbound sales reached $4.93 billion, exceeding consensus, as combined Mounjaro and Zepbound volumes drove 48% company revenue growth to $23 billion despite a 13% decline in realized prices from rebates and access concessions. Analysts project continued expansion, with one model estimating $5.21 billion for Q3 Zepbound on higher prescription starts and supply additions, though Medicare bridge pricing and competitive oral options introduce downside risks. Multiple 2026 revenue guidance lifts reflect strong volume momentum, positioning the quarter as a key test of sustained market-implied growth assumptions.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于1H6H1D7D30DALL
View resolved

警惕外部链接哦。
警惕外部链接哦。
常见问题